KD-3010 

KD-3010 is a potent, orally active, and selective PPARδ agonist.

To determine whether PPARδ agonists are beneficial in experimental liver fibrosis, mice are treated orally with a PPARδ agonist, KD-3010, or with the well-validated PPARδ agonist GW501516. KD-3010, but not GW501516, shows hepatoprotective and antifibrotic effects in liver fibrosis induced by carbon tetrachloride (CCl₄) or bile duct ligation (BDL). Liver injury is induced by repeated injections of CCl₄, and mice are treated daily with vehicle, the widely used PPARδ agonist GW501516, or the PPARδ agonist KD-3010 by oral gavage. Control oil-injected mice do not show any liver damage. Liver injury consisting of hepatocyte death and inflammation is seen in the vehicle- or GW501516-treated group injected with CCl₄ on H&E-stained liver sections but is markedly reduced in the KD3010-treated group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

670.72

C₃₀H₃₃F₃N₂O₈S₂

934760-92-6

O=C([C@H]1CC2=C(C(S(=O)(N3[C@H](C)CN(C4=CC=C(OC(F)(F)F)C=C4)C[C@@H]3C)=O)=CC=C2)C1)O.OS(=O)(C5=CC=C(C)C=C5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Iwaisako K, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012 May 22;109(21):E1369-76.  [Content Brief]